Clofarabine

Active ingredient: Clofarabine

In short: Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.

Forms & strengthsInjection: 20 mg/20 m L (1 mg/m L) clear colorless solution in single-dose vial
LabelNovadoz Pharmaceuticals LLC
Label updatedSep 02, 2026

What is Clofarabine used for?

Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.

Clofarabine dosage

Administer the recommended pediatric dose of 52 mg/m2 as an intravenous infusion over 2 hours daily for 5 consecutive days.

Repeat treatment cycles following recovery or return to baseline organ function, approximately every 2 to 6 weeks. Base dosage on the patient’s body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, do not administer other medications through the same intravenous line. Administer subsequent cycles no sooner than 14 days from the starting day of the previous cycle and provided the patient’s ANC is ≥0.75 × 109/L.

Provide supportive care,such as intravenous fluids, antihyperuricemic treatment, and alkalinize urine throughout the 5 days of clofarabine injection administration to reduce the effects of tumor lysis and other adverse reactions.

Discontinue clofarabine injection if hypotension develops during the 5 days of administration.

Monitor renal and hepatic function during the 5 days of clofarabine injection administration .

Monitor patients taking medications known to affect blood pressure. Monitor cardiac function during administration of clofarabine injection.

Reduce the dose by 50% in patients with creatinine clearance (CrCL) between 30 and 60 m L/min. There is insufficient information to make a dosage recommendation in patients with CrCL less than 30 mL/min .

Consider prophylactic antiemetic medications as clofarabine injection is moderately emetogenic.

Consider the use of prophylactic steroids to mitigate Systemic Inflammatory Response Syndrome (SIRS) or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, and pulmonary edema).

Minimize exposure to drugs with known renal toxicity during the 5 days of clofarabine injection administration since the risk of renal toxicity may be increased.

Avoid concomitant use of medications known to induce hepatic toxicity.

Hematologic Toxicity

Ifa patient experiences a Grade 4 neutropenia (ANC <0.5 x 109/L) lasting >4 weeks, reduce dose by 25% for the next cycle.

Non-hematologic Toxicity

Withhold clofarabine injection if a patient develops a clinically significant infection, until the infection is controlled, then restart at the full dose.

Withhold clofarabine injection for a Grade 3 non-infectious non-hematologic toxicity (excluding transient elevations in serum transaminases and/or serum bilirubin and/or nausea/vomiting controlled by antiemetic therapy). Re-institute clofarabine injection administration at a 25% dose reduction when resolution or return to baseline.

Discontinue clofarabine injection administration for a Grade 4 non-infectious non-hematologic toxicity. …

How to take Clofarabine — instructions & advice from the label

Hematologic Toxicity

Advise patients to return for regular blood counts and to report any symptoms associated with hematologic toxicity (such as weakness, fatigue, pallor, shortness of breath, easy bruising, petechiae, purpura, fever) to their physician .

Infection

Advise patients of the signs or symptoms of infection (e.g., fever) and report to the physician immediately if any occur .

Hepatic and Renal Toxicity

Advise patients to avoid medications including over the counter and herbal medications, which may be hepatotoxic or nephrotoxic, during the 5 days of clofarabine injection administration. Also, advise patients of the possibility of developing liver function abnormalities and to immediately report signs or symptoms of jaundice. Advise patients of the signs or symptoms of renal failure/acute renal failure .

Systemic Inflammatory Response Syndrome (SIRS)/Capillary Leak Syndrome

Advise patients of the signs or symptoms of SIRS, such as fever, tachycardia, tachypnea, dyspnea and symptoms suggestive of hypotension .

Pregnancy

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. …

Warnings & precautions

Do not take this medicine if: None.

Clofarabine injection causes myelosuppression which may be severe and prolonged. Febrile neutropenia occurred in 55% and non-febrile neutropenia in an additional 10% of pediatric patients in clinical trials. At initiation of treatment, most patients in the clinical studies had hematological impairment as a manifestation of leukemia. Myelosuppression is usually reversible with interruption of clofarabine injection treatment and appears to be dose- dependent. Monitor complete blood counts .

Serious and fatal hemorrhage, including cerebral, gastrointestinal and pulmonary hemorrhage, has occurred. The majority of the cases were associated with thrombocytopenia. Monitor platelets and coagulation parameters and treat accordingly .

Clofarabine injection increases the risk of infection, including severe and fatal sepsis, and opportunistic infections. At baseline, 48% of the pediatric patients had one or more concurrent infections. A total of 83% of patients experienced at least one infection after clofarabine injection treatment, including fungal, viral and bacterial infections. Monitor patients for signs and symptoms of infection, discontinue clofarabine injection, and treat promptly.

Administration of clofarabine injection may result in tumor lysis syndrome associated with the break-down metabolic products from peripheral leukemia cell death. Monitor patients undergoing treatment for signs and symptoms of tumor lysis syndrome and initiate preventive measures including adequate intravenous fluids and measures to control uric acid.

Clofarabine injection may cause a cytokine release syndrome (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that may progress to the systemic inflammatory response syndrome (SIRS) with capillary leak syndrome and organ impairment which may be fatal. Monitor patients frequently for these conditions. …

Clofarabine side effects

The following clinically significant adverse reactions are discussed in greater detail in other sections of the label:

Myelosuppression

Hemorrhage

Serious Infections

Hyperuricemia (tumor lysis syndrome)

Systemic Inflammatory Response Syndrome (SIRS) and Capillary Leak Syndrome

Venous Occlusive Disease of the Liver

Hepatotoxicity

Renal Toxicity

Enterocolitis

Skin Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The data described below reflect exposure to clofarabine injection in 115 pediatric patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL) (70 patients) or Acute Myelogenous Leukemia (AML) (45 patients).In total, 115 pediatric patients treated in clinical trials received the recommended dose of clofarabine injection 52 mg/m2 daily x5. The median number of cycles was 2. The median cumulative amount of clofarabine injection received by pediatric patients during all cycles was 540 mg.Most common adverse reactions (≥25%): vomiting, nausea, diarrhea, febrile neutropenia, pruritus, headache, bacteremia, pyrexia, rash, tachycardia, abdominal pain, chills, fatigue, anorexia, pain in extremity, hypotension, epistaxis, and petechiae. …

About this medicine

Clofarabine injection contains clofarabine, a purine nucleoside metabolic inhibitor.

The chemical name of clofarabine is 2-chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-9H-purine-6-amine. Its molecular formula is C10H11Cl FN5O3 with a molecular weight of 303.68 Daltons.

The molecular structure of clofarabine is:

Clofarabine

Clofarabine injection (1 mg/m L) is supplied in a 20 m L, single-dose vial. The 20 m L vial contains 20 mg clofarabine formulated in 20 m L unbuffered normal saline (comprised of Water for Injection, USP, and Sodium Chloride, USP). The p H range of the solution is 4.5 to 7.5. The solution is sterile, clear and practically colorless, and is preservative-free.

How it works: Clofarabine is sequentially metabolized intracellularly to the 5’-monophosphate metabolite by deoxycytidine kinase and mono- and di-phospho-kinases to the active 5’-triphosphate metabolite. Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal to or greater than that of the natural substrate, deoxycytidine. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 26b2de66-6518-49ab-820e-492454cbc873. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate